All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Chapter Three - Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F17%3A43912818" target="_blank" >RIV/00216208:11120/17:43912818 - isvavai.cz</a>

  • Alternative codes found

    RIV/00216208:11130/17:10364915 RIV/00216208:11150/17:10364915 RIV/00179906:_____/17:10364915 RIV/00064173:_____/17:N0000184 RIV/00064203:_____/17:10364915

  • Result on the web

    <a href="https://doi.org/10.1016/bs.ircmb.2016.09.003" target="_blank" >https://doi.org/10.1016/bs.ircmb.2016.09.003</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1016/bs.ircmb.2016.09.003" target="_blank" >10.1016/bs.ircmb.2016.09.003</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Chapter Three - Rationale for the Combination of Dendritic Cell-Based Vaccination Approaches With Chemotherapy Agents

  • Original language description

    Owing to their central role in the initiation and regulation of antitumor immunity, dendritic cells (DCs) have been widely tested for use in cancer immunotherapy. Despite several encouraging clinical applications, existing DC-based immunotherapy efforts have yielded inconsistent results. Recent work has identified strategies that may allow for more potent DC-based vaccines, such as the combination with antitumor agents that have the potential to synergistically enhance DC functions. Selected cytotoxic agents may stimulate DCs either by directly promoting their maturation or through the induction of immunogenic tumor cell death. Moreover, they may support DC-induced adaptive immune responses by disrupting tumor-induced immunosuppressive mechanisms via selective depletion or inhibition of regulatory subsets, such as myeloid-derived suppressor cells and/or regulatory T cells (Tregs). Here, we summarize our current knowledge on the capacity of anticancer chemotherapeutics to modulate DC phenotype and functions and the results of ongoing clinical trials evaluating the use of DC-based immunotherapy in combination with chemotherapy in cancer patients.

  • Czech name

  • Czech description

Classification

  • Type

    C - Chapter in a specialist book

  • CEP classification

  • OECD FORD branch

    30204 - Oncology

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2017

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Book/collection name

    International Review of Cell and Molecular Biology; Vol. 330

  • ISBN

    978-0-12-812467-3

  • Number of pages of the result

    42

  • Pages from-to

    115-156

  • Number of pages of the book

    352

  • Publisher name

    Academic Press

  • Place of publication

    Cambridge

  • UT code for WoS chapter

    000452397000003